Quality of Anticoagulation with Vitamin K Antagonists

Clinical Cardiology

Volumn 38, Issue 6, 2015, Pages 357-364

  Bertomeu González, Vicente ^a   Anguita, Manuel ^b,c   Moreno Arribas, José ^a   Cequier, Ángel ^b,d   Muñiz, Javier ^e   Castillo Castillo, Jesús ^a   Sanchis, Juan ^f   Roldán, Inmaculada ^g   Marin, Francisco ^h   Bertomeu Martínez, Vicente ^a,b  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b Research Agency of the Spanish Society of Cardiology   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITY OF A CORUÑA   (Spain)

^f UNIVERSITY OF VALENCIA   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG QUALITY; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART RATE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PROSPECTIVE STUDY; ANTAGONISTS AND INHIBITORS; COMPLICATION; HEALTH CARE QUALITY; MIDDLE AGED; REGISTER; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; REGISTRIES; STROKE; VITAMIN K;

EID: 84931956191     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22397     Document Type: Article

References (23)

1. Wilke T, Groth A, Mueller S, et al., Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Eur Soc Cardiol. 2013; 15: 486-493.
2. Mearns ES, White CM, Kohn CG, et al., Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014; 24: 12-14.
3. van Walraven C, Jennings A, Oake N, et al., Effect of study setting on anticoagulation control: a systematic review and meta-regression. Chest. 2006; 129: 1155-1166.
4. Wan Y, Heneghan C, Perera R, et al., Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008; 1: 84-91.
5. Baker WL, Cios DA, Sander SD, et al., Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009; 15: 244-252.
6. Cios DA, Baker WL, Sander SD, et al., Evaluating the impact of study-level factors on warfarin control in US-based primary studies: a meta-analysis. Am J Health Syst Pharm. 2009; 66: 916-925.
7. Lip GY, Nieuwlaat R, Pisters R, et al., Refining clinical risk stratification for predicting stroke in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137: 263-272.
8. Pisters R, Lane DA, Nieuwlaat R, et al., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100.
9. Charlson ME, Pompei P, Ales KL, et al., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40: 373-383.
10. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al., A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69: 236-239.
11. Connolly SJ, Pogue J, Eikelboom J, et al., Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118: 2029-2037.
12. 2 score. Chest. 2013; 144: 1555-1563.
13. Qualls LG, Greiner MA, Eapen ZJ, et al., Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims. Clin Cardiol. 2013; 36: 757-765.
14. Gadisseur AP, Breukink-Engbers WG, et al., Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized clinics in the Netherlands: a randomized clinical trial. Arch Intern Med. 2003; 163: 2639-2646.
15. Anderson JL, Horne BD, Stevens SM, et al., Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007; 116: 2563-2570.
16. Clua-Espuny JL, Lechuga-Duran I, Bosch-Princep R, et al., Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study. Rev Esp Cardiol (Engl Ed). 2013; 66: 545-552.
17. Rodríguez-Mañero M, Otero-Raviña F, García-Seara J, et al., Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin: results from the AFBAR Study. Rev Esp Cardiol (Engl Ed). 2014; 67: 890-897.
18. Cotté FE, Benhaddi H, Duprat-Lomon I, et al., Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. Clin Ther. 2014; 36: 1160-1168.
19. Le Heuzey JY, Ammentorp B, Darius H, et al., Differences among Western European countries in anticoagulation management of atrial fibrillation: data from the PREFER IN AF registry. Thromb Haemost. 2014; 111: 833-841.
20. Arnsten JH, Gelfand JM, Singer DE,. Determinants of compliance with anticoagulation: a case-control study. Am J Med. 1997; 103: 11-13.
21. Platt AB, Localio AR, Brendinger AM, et al., Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008; 17: 853-860.
22. Kulkarni SP, Alexander KP, Lytle B, et al., Long-term adherence with cardiovascular drug regimens. Am Heart J. 2006; 151: 185-191.
23. Pengo V, Pegoraro C, Cucchini U, et al., Worldwide management of oral anticoagulation therapy: the ISAM study. J Thromb Thrombolysis. 2006; 211: 73-77.